6H-pyrido<4,3-b>carbazole | 243-30-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 6H-pyrido<4,3-b>carbazole
• 英文别名: 11-Demethylellipticin；10H-Pyrido<4,3-b>carbazol；6H-Pyrido<4,3-b>carbazol；Nor-5,11-dimethylellipticine；6H-pyrido[4,3-b]carbazole；6H-Pyrido[4,3-b]carbazol；bisdesmethyl-17,21-ellipticine；pyrido[4,3-b]carbazole；6H-Pyrido[4,3-b]carbazole
• CAS: 243-30-1
• 化学式: C₁₅H₁₀N₂
• 分子量: 218.258
• InChiKey: KSEHRXUCGLUTMA-UHFFFAOYSA-N

物化性质

• 熔点：
  283-284 °C
• 沸点：
  488.6±18.0 °C(Predicted)
• 密度：
  1.336±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  17
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  28.7
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  1,2-Dihydro-10H-pyrido<4,3-b>carbazol 在 palladium on activated charcoal 、 萘烷 作用下， 生成 6H-pyrido<4,3-b>carbazole
  参考文献：
  名称：

  关于生物碱的组成olivacin，guatambuin和u-生物碱D. Asperdosperma生物碱，第5部分

  摘要：

  的基本结构白坚木属生物碱olivacin，guatambuin（U-生物碱C）和u-生物碱d被澄清。

  DOI：

  10.1002/hlca.19590420643

文献信息

• 2-acyl indole derivatives and their use as antitumor agents
  申请人：——

  公开号：US20020091124A1

  公开（公告）日：2002-07-11

  The invention relates to novel indole and heteroindole derivatives of the formula I 1 to their tautomers, their stereoisomers, their mixtures and their salts, to their preparation and to the use of indole derivatives of the formula I as antitumor agents.

  这项发明涉及到式I的新型吲哚和杂吲哚衍生物，以及它们的互变异构体、立体异构体、混合物和盐，以及它们的制备和将式I的吲哚衍生物用作抗肿瘤药剂。
• [EN] SMALL MOLECULES THAT TARGET THE RNA THAT CAUSES ALS<br/>[FR] PETITES MOLÉCULES CIBLANT L'ARN PROVOQUANT LA SLA
  申请人：EXPANSION THERAPEUTICS INC

  公开号：WO2022055922A1

  公开（公告）日：2022-03-17

  Disclosed herein are compounds that selectively bind an expanded transcribed repeat r(G4C2)exp, prevent sequestration of RNA-binding proteins, and inhibit translation of repeat associated non-ATG (RAN) translation responsible for generation of toxic dipeptide repeats underlying diseases such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The compounds and their pharmaceutical compositions are useful in treating a disease or condition characterized by an expanded G4C2 repeat RNA (r(G4C2)exp), such as ALS and FTD.

  本文披露了一些化合物，这些化合物能选择性地结合扩增的转录重复r(G4C2)exp，防止RNA结合蛋白的封存，并抑制与重复相关的非ATG（RAN）翻译，从而负责生成毒性二肽重复，导致包括肌萎缩侧索硬化症（ALS）和额颞叶痴呆（FTD）在内的疾病。这些化合物及其药物组合物对治疗由扩增的G4C2重复RNA（r(G4C2)exp）特征的疾病或状况，如ALS和FTD，具有用处。
• [EN] AZA-ELLIPTICINE ANALOGS, METHODS OF SYNTHESIS AND METHODS OF TREATMENT<br/>[FR] ANALOGUES D'AZA-ÉLLIPTICINE, PROCÉDÉS DE SYNTHÈSE ET PROCÉDÉS DE TRAITEMENT
  申请人：MUSC FOUND FOR RES DEV

  公开号：WO2015179218A1

  公开（公告）日：2015-11-26

  In some aspects, the present invention relates to aza-ellipticine compounds of the formula: wherein the variables are as defined herein. The application also provides novel methods of preparing aza-ellipticine compounds, methods of using the compounds, and pharmaceutical compositions thereof.

  在某些方面，本发明涉及式子如下的氮杂-椭圆咔啉化合物：其中变量如本文所定义。该申请还提供了制备氮杂-椭圆咔啉化合物的新方法，使用该化合物的方法和制药组合物。
• Selective cellular targeting: multifunctional delivery vehicles, multifunctional prodrugs, use as antineoplastic drugs
  申请人：Drug Innovation & Design, Inc.

  公开号：US20030138432A1

  公开（公告）日：2003-07-24

  The present invention relates to the compositions, methods, and applications of a novel approach to selective cellular targeting. The purpose of this invention is to enable the selective delivery and/or selective activation of effector molecules to target cells for diagnostic or therapeutic purposes. The present invention relates to multi-functional prodrugs or targeting vehicles wherein each functionality is capable of enhancing targeting selectivity, affinity, intracellular transport, activation or detoxification. The present invention also relates to ultra-low dose, multiple target, multiple drug chemotherapy and targeted immunotherapy for cancer treatment.

  本发明涉及一种新的选择性细胞靶向的组合物、方法和应用。本发明的目的是为了实现对目标细胞的选择性输送和/或选择性激活效应分子，以进行诊断或治疗。本发明涉及多功能前药或靶向载体，其中每个功能都能增强靶向选择性、亲和力、细胞内转运、激活或解毒。本发明还涉及超低剂量、多靶点、多药物化疗和靶向免疫疗法，用于癌症治疗。
• 2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations
  申请人：——

  公开号：US20040147022A1

  公开（公告）日：2004-07-29

  Compositions comprising first and second oligomers are provided wherein at least a portion of the first oligomer is capable of hybridizing with at least a portion of the second oligomer, at least a portion of the first oligomer is complementary to and capable of hybridizing to a selected target nucleic acid, and at least one of the first or second oligomers includes a modified sugar and/or backbone modification. In some embodiments the modification is a 2′-OCH 3 substituent group on a sugar moiety. Oligomer/protein compositions are also provided comprising an oligomer complementary to and capable of hybridizing to a selected target nucleic acid and at least one protein comprising at least a portion of an RNA-induced silencing complex (RISC), wherein at least one nucleotide of the oligomer has a modified sugar and/or backbone modification.

  提供了包含第一和第二寡核苷酸的组合物，其中第一寡核苷酸的至少一部分能够与第二寡核苷酸的至少一部分杂交，第一寡核苷酸的至少一部分与所选目标核酸互补并能够杂交，第一或第二寡核苷酸中至少有一个包含修饰糖和/或骨架修饰。在某些实施例中，修饰是在糖基上的2'-OCH3取代基。还提供了寡核苷酸/蛋白质组合物，其中包括与所选目标核酸互补并能够杂交的寡核苷酸和至少一种蛋白质，该蛋白质包括RNA诱导沉默复合物（RISC）的至少一部分，其中至少一核苷酸具有修饰糖和/或骨架修饰。